Internal and Emergency Medicine

, Volume 13, Issue 6, pp 873–880 | Cite as

Epigallocatechin-3-gallate tolerability and impact on survival in a cohort of patients with transthyretin-related cardiac amyloidosis. A single-center retrospective study

  • Francesco CappelliEmail author
  • Raffaele Martone
  • Giulia Taborchi
  • Sofia Morini
  • Simone Bartolini
  • Paola Angelotti
  • Silvia Farsetti
  • Carlo Di Mario
  • Federico Perfetto


Transthyretin-related (ATTR) cardiac amyloidosis is currently lacking a disease-modifying therapy. Despite demonstration of effectiveness in halting amyloid deposition, no study focused on epigallocatechin-3-gallate (EGCG) impact on patient survival. We sought to explore prognostic impact of EGCG in a cohort of lone cardiac ATTR patients. From the Florence Tuscan Regional Amyloid Centre database, we retrospectively selected ATTR patients treated with EGCG (675mg daily dose) for a minimum of 9 months, between March 2013 and December 2016. As a control group, we selected ATTR patients who received guideline-directed medical therapy alone. End point of the study was time to all cause death or cardiac transplantation. Sixty-five patients (30 treatment groups vs. 35 control groups) had a median follow-up of 691 days. There were no differences in baseline characteristics between groups. Five deaths occurred in EGCG group versus eight in control group; one patient underwent effective cardiac transplantation in EGCG group. There was no difference in survival estimates between EGCG and control group (60 ± 15% vs. 61 ± 12%, p = 0.276). EGCG was well tolerated, without major safety concerns. In a real-world cohort of ATTR patients with lone cardiac involvement, EGCG was a safe therapeutic option, but was not associated with survival improvement.


Epigallocatechin-3-gallate Transthyretin amyloid Cardiac amyloid Survival 


Compliance with Ethical Standards

Conflict of interest

The authors declare that they have no conflict of interest.

Statement of human and animal rights

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.


  1. 1.
    Perfetto F, Cappelli F, Bergesio F, Ciuti G, Porciani MC, Padeletti L (2013) Moggi Pignone A cardiac amyloidosis: the heart of the matter. Intern Emerg Med 8:191–203CrossRefPubMedGoogle Scholar
  2. 2.
    Wechalekar AD, Gillmore JD, Hawkins PN (2016) Systemic amyloidosis. Lancet 387(10038):2641–2654CrossRefPubMedGoogle Scholar
  3. 3.
    Grogan M, Scott CG, Kyle RA, Zeldenrust SR, Gertz MA, Lin G, Klarich KW, Miller WL, Maleszewski JJ, Dispenzieri A (2016) Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system. J Am Coll Cardiol 68(10):1014–1020CrossRefPubMedGoogle Scholar
  4. 4.
    Berk JL, Suhr OB, Obici L, Sekijima Y, Zeldenrust SR, Yamashita T et al (2013) Repurposing diflunisal for familial amyloid polyneuropathy a randomized clinical trial. JAMA 310:2658–2667CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Obici L, Cortese A, Lozza A, Lucchetti J, Gobbi M, Palladini G, Perlini S, Saraiva MJ, Merlini G (2012 Jun) Doxycycline plus tauroursodeoxycholic acid for transthyretin amyloidosis: a phase II study. Amyloid 19(Suppl 1):34–36CrossRefPubMedGoogle Scholar
  6. 6.
    Maurer MS, Elliott P, Merlini G, Shah SJ, Cruz MW, Flynn A, Gundapaneni B, Hahn C, Riley S, Schwartz J, Sultan MB, Rapezzi C (2017) ATTR-ACT study investigators. Design and rationale of the phase 3 ATTR-ACT clinical trial (Tafamidis in transthyretin cardiomyopathy clinical trial). Circ Heart Fail.
  7. 7.
    Suhr OB, Coelho T, Buades J, Pouget J, Conceicao I, Berk J, Schmidt H, Waddington-Cruz M, Campistol JM et al (2015) Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi-dose study. Orphanet J Rare Dis 10:109CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Adams D, Suhr OB, Dyck PJ, Litchy W, Leahy RG, Chen J, Gollob J (2017) Coelho T Trial design and rationale for APOLLO, a phase 3, placebo-controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy. BMC Neurol 17:181CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Ehrnhoefer DE, Bieschke J, Boeddrich A, Herbst M, Masino L, Lurz R, Engemann S, Pastore A (2008) Wanker EE EGCG redirects amyloidogenic polypeptides into unstructured, offpathway oligomers. Nat Struct Mol Biol 15:558–566CrossRefPubMedGoogle Scholar
  10. 10.
    Ferreira N, Cardoso I, Domingues MR, Vitorino R, Bastos M, Ba G, Saraiva MJ, Almeida MR (2009) Binding of epigallocatechin- 3-gallate to transthyretin modulates) its amyloidogenicity. FEBS Lett 19(583):3569–3576CrossRefGoogle Scholar
  11. 11.
    Ferreira N, Saraiva MJ (2012) Almeida MR epigallocatechin-3-gallate as a potential therapeutic drug for TTR-related amyloidosis: ‘‘in vivo’’ evidence from FAP mice models. PLoS ONE 7(1):e29933CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Ferreira N, Saraiva MJ, Almeida M (2012) Natural polyphenols as modulators of TTR Amyloidogenesis in vitro and in vivo evidences towards therapy. Amyloid 19(S1):39–42Google Scholar
  13. 13.
    Kristen AV, Lehrke S, Buss S, Mereles D, Steen H, Ehlermann P, Hardt S, Giannitsis E, Schreiner R, Haberkorn U, Schnabel PA, Linke RP, Rocken C, Wanker EE, Dengler TJ, Altland K, Katus HA (2012) Green tea halts progression of cardiac transthyretin amyloidosis: an observational report. Clin Res Cardiol 101(10):805–813CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Mereles D, Buss SJ, Hardt SE, Hunstein W, Katus HA (2010) Effects of the main green tea polyphenol epigallocatechin-3-gallate on cardiac involvement in patients with AL amyloidosis. Clin Res Cardiol 99:483–490Google Scholar
  15. 15.
    Aus dem Siepen F, Buss SJ, Andre F, Seitz S, Giannitsis E, Steen H, Katus HA, Kristen AV (2015) Extracellular remodeling in patients with wild-type amyloidosis consuming epigallocatechin-3-gallate: preliminary results of T1 mapping by cardiac magnetic resonance imaging in a small single center study. Clin Res Cardiol 104(8):640–647Google Scholar
  16. 16.
    Aus dem Siepen F, Bauer R, Aurich M, Buss SJ, Steen H, Altland K, Katus HA, Kristen AV (2015) Green tea extract as a treatment for patients with wild-type transthyretin amyloidosis: an observational study. Drug Design Dev Therapy 9 6319–6325Google Scholar
  17. 17.
    Lambert JD, Kennett MJ, Sang S, Reuhl KR, Ju J, Yang CS (2010) Hepatotoxicity of high oral dose (-)-epigallocatechin-3-gallate in mice. Food Chem Toxicol 48(1):409–416CrossRefPubMedGoogle Scholar
  18. 18.
    Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A et al (2016) Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation 133(24):2404–2412CrossRefPubMedGoogle Scholar
  19. 19.
    Gillmore JD, Damy T, Fontana M, Hutchinson M, Lachmann HJ, Martinez-Naharro A, Quarta CC, Rezk T, Whelan CJ, Gonzalez-Lopez E, Lane T, Gilbertson JA, Rowczenio D, Petrie A, Hawkins PN (2017) A new staging system for cardiac transthyretin amyloidosis. Eur Heart J. PubMedPubMedCentralCrossRefGoogle Scholar
  20. 20.
    Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, Flachskampf FA, Foster E, Goldstein SA, Kuznetsova T, Lancellotti P, Muraru D, Picard MH, Rietzschel ER, Rudski L, Spencer KT, Tsang W, Voigt JU (2015) Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 28(1):1–39.e14Google Scholar
  21. 21.
    Gertz MA, Comenzo R, Falk RH et al (2005) Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th international symposium on amyloid and amyloidosis. Am J Hematol 79:319–328CrossRefPubMedGoogle Scholar
  22. 22.
    Cappelli F, Frusconi S, Bergesio F, Grifoni E, Fabbri A, Giuliani C, Falconi S, Bonifacio S, Perfetto F (2016) The Val142Ile transthyretin cardiac amyloidosis: not only an afro American pathogenic variant? A single center Italian experience. J Cardiovasc Med 2016 17(2):122–5.44Google Scholar
  23. 23.
    Rapezzi C, Quarta CC, Obici L, Perfetto F, Longhi S, Salvi F, Biagini E, Lorenzini M, Grigioni F, Leone O, Cappelli F, Palladini G, Rimessi P, Ferlini A, Arpesella G, Pinna AD, Merlini G, Perlini S (2013 Feb) Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective. Eur Heart J 34(7):520–528CrossRefPubMedGoogle Scholar
  24. 24.
    Perfetto F, Cappelli F, Bergesio F (2011 Jun) Asymptomatic homozygous gene carrier in afamily with Ile68Leu ATTR amyloidosis: a new endemic region in northern Tuscany? J Cardiovasc Med (Hagerstown). 12(6):450–451CrossRefGoogle Scholar
  25. 25.
    Hunstein W (2007) Epigallocathechin-3-gallate in AL amyloidosis: a new therapeutic option? Blood 110:2216CrossRefPubMedGoogle Scholar

Copyright information

© SIMI 2018

Authors and Affiliations

  • Francesco Cappelli
    • 1
    • 2
    Email author
  • Raffaele Martone
    • 2
  • Giulia Taborchi
    • 2
  • Sofia Morini
    • 2
  • Simone Bartolini
    • 2
  • Paola Angelotti
    • 1
  • Silvia Farsetti
    • 1
  • Carlo Di Mario
    • 2
  • Federico Perfetto
    • 1
  1. 1.Tuscan Regional Amyloid CenterCareggi University HospitalFlorenceItaly
  2. 2.Interventional Structural Cardiology DivisionCareggi University HospitalFlorenceItaly

Personalised recommendations